Seattle Children’s researchers have published a study that has uncovered a deeper understanding of why people who have had mild cases of the novel coronavirus 2019 (COVID-19) lose functional antibodies within a few months.
Last year, while seeing the bulk of research analysis focused on severe cases of COVID-19, a team of researchers led by Seattle Children’s Research Institute’s Center for Global Infectious Disease Research, the largest pediatric infectious disease research center in the country, sought to evaluate the immune responses that occur after people recover from more mild cases of COVID-19. Mild cases, researchers say, are the most common type of cases. Published in Cell Reports Medicine, a team of researchers found that while antibodies did persist over time, they were not the functional antibodies needed to protect someone from reinfection.
The study evaluated a cohort of 34 adults, ranging in age from 24-74 for up to six months. It characterizes antibody responses to infection and does not investigate T cell or vaccine responses. Antibody responses to vaccination are likely to behave very differently and have different longevity.
At first, researchers found a sustained and maturing presence of an antibody called Immunoglobulin G (IgG) among participants, which should normally mean protection from infection of a virus would improve, says Dr. Noah Sather, a principal investigator at Seattle Children’s Research Institute and associate professor at the University of Washington.
Read full post »